Navigation Links
Sinovac Reports Unaudited Second Quarter 2012 Financial Results
Date:8/15/2012

BEIJING, Aug. 15, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (the company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter financial results for the period ended June 30, 2012. Sinovac is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccine products. The company is making efforts to implement its business strategy to expand its range of product portfolio for both domestic and international markets. The Company has built a solid foundation of commercialized vaccines for hepatitis A, hepatitis A&B and seasonal flu. It has developed specialized pandemic flu vaccines for the H1N1 (swine flu) and H5N1 (avian flu) strains that have been stockpiled by Chinese government. Sinovac also has an extensive human vaccine pipeline inclusive of EV71 and pneumococcal vaccine candidates.

2012 Second Quarter Financial Highlights (year-over-year comparisons to second quarter 2011)

  • Total sales of core vaccines (hepatitis A, hepatitis A&B, and seasonal influenza) were $9.4 million, up 17.6% with Bilive (hepatitis A&B) sales up 25.8%. Total sales decreased 40.2%, compared to the same quarter in 2011 due to the non-core government stockpile H5N1 pandemic flu vaccine sales of $7.7 million booked during that quarter.
  • Gross profit margin based on core vaccine sales was 85.3%, compared to 84.2% in the same period of last year. Overall gross profit margin for the same period 2011 was 68.8%, due to revenue recognition of H5N1 vaccine with lower gross margin in the second quarter of 2011.
  • Net loss attributable to common stockholders was $0.9 million, or $0.02 per basic and diluted share.
  • Cash and cash equivalents totaled $89.4 million as of June 30, 2012, compared to $94.5 million as of March 31, 2012 and $
    '/>"/>

  • SOURCE Sinovac Biotech Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
    2. Sinovac Schedules 2012 Annual Meeting of Shareholders
    3. Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
    4. Sinovac Reports Unaudited First Quarter 2012 Financial Results
    5. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
    6. Nephros Reports Second Quarter 2012 Financial Results
    7. Tengion Reports Second Quarter 2012 Financial Results
    8. Synthetic Biologics Reports Second Quarter 2012 Financial Results
    9. Vermillion Reports Second Quarter 2012 Results
    10. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
    11. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from ... China,s orthopedic instrument industry has seen ... rising from 3.28 billion yuan in 2006 to 9.85 ...
    (Date:1/15/2014)... 2014 AARP Foundation today announced it has established a ... the severe cold weather that has gripped much of the ... in need; so to support these emergency relief efforts AARP ... which could mean up to $500,000 in aid. The matching ...
    (Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
    Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
    ... Through Joint Venture Between Bristol-Myers Squibb and ... Its Kind in HIV Treatment -, PRINCETON, N.J. ... Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz 600 mg/emtricitabine ... commercialization in the,27 countries of the European Union, as ...
    ... novel combination of drugs was,able to completely eradicate ... for the effective treatment of patients with advanced,metastatic ... University,School of Medicine presented the results of a ... pulmonary metastases in female SCID,mice., Paclitaxel is ...
    Cached Medicine Technology:European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9New Drug Combination is Able to Eradicate Breast Metastases in Mice 2
    (Date:4/18/2014)... 18, 2014) Benaroya Research Institute at Virginia Mason ... a particular molecule in metastatic breast cancer reduces both ... lung metastases. BRI scientists have found in models of ... by 60 - 80 percent and can keep the ... $1.8 million five-year grant comes from the National Cancer ...
    (Date:4/18/2014)... ― A new study in the American Journal ... Google searches reveals a recurring pattern that could be ... Investigators from San Diego State University, the Santa Fe ... "healthy" Google searches (searches that included the term healthy ... the U.S. from 2005 to 2012. They found that ...
    (Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
    (Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
    (Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
    Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2
    ... exposure can produce more than some tanners may bargain ... to treat skin eruptions, according to research conducted by ... "There are many reasons to be cautious ... beds to ,self-treat, skin eruptions," said Jeffrey B. Travers, ...
    ... small subset of normal white blood cells in the body ... The study, led by investigators at The Ohio State ... and Richard J. Solove Research Institute (OSUCCC James), shows ... subset of white blood cells called NKT cells. NKT cells ...
    ... , CHAMPAIGN, lll. A review of more than 160 ... compelling evidence" that all else being equal happy ... their unhappy peers. The study, in the journal ... review so far of the evidence linking happiness to health ...
    ... (HealthDay News) -- The use of virtual colonoscopies at U.S. ... not covered by Medicare, a new study finds. Also ... uses virtual reality technology to provide doctors with a 3-D ... entire colon and rectum. CTC is an alternative to colonoscopy ...
    ... WIREs Nanomedicine and Nanobiotechnology explores how nanotechnology ... marked impact on the therapeutic and diagnostic measures available ... a meterto achieve tasks that would be difficult at ... and can enter cells, making them useful for drug ...
    ... been on the rise in the United States. In fact, ... vehicle crash fatalities to become the leading cause of injury ... reported, they are only the tip of the iceberg. ... Research and Policy of The Research Institute at Nationwide Children,s ...
    Cached Medicine News:Health News:Tanning bed exposure can be deadly when complicated by medication reactions 2Health News:A small subset of normal white blood cells gives rise to a rare leukemia, study shows 2Health News:Study: Happiness improves health and lengthens life 2Health News:Surgeons predict the future of nanomedicine in practice 2Health News:New study: Medical and financial impact of drug-related poisonings treated in US EDs 2
    ... unique combination of topography, auto-refraction and keratometer ... three devices. The compactness of this instrument ... perfect space and cost saving solution. ... examination time and easy handling makes working ...
    ... SP-3000 covers all needs regarding pachymetry in ... care., ,Compact design, colored touch-screen and "quick ... an "easy-to-use unit.,The wide measurement range from ... the possibility to measure very thin or ...
    The PillCam™ ESO video capsule is specifically designed to view the inner lining of the Esophagus. The capsule is equipped with miniature cameras on both ends and is about the size of a multi-v...
    ... Wave combines three advanced technologies - ... easy-to-use refractive diagnostic workstation. Now, with ... refraction, corneal topography, optical path difference ... Wave allows you to evaluate your ...
    Medicine Products: